INTRODUCING: EVERY 2-MONTH VOCABRIA (CABOTEGRAVIR) + REKAMBYS (RILPIVIRINE)
Here you can find all the information you need about VOCABRIA + REKAMBYS.
*Monthly VOCABRIA + REKAMBYS has non-inferior efficacy to daily oral ARV therapy. At week 48 (primary endpoint), 1.6% (5/308) of participants on Monthly VOCABRIA + REKAMBYS and 1.0% of participants on Daily oral ARV therapy has HIV-1 RNA levels of ≥50 copies/mL (adjusted treatment difference 0.6, 95% CI: -1.2, 2.5). 3
Graphs developed from reference 4 by ViiV Healthcare
Additional analyses show that the likelihood of CVF may be reduced by exercising caution when considering in patients with a combination of at least 2 of the following: incomplete resistance testing and treatment history; HIV subtype A1/A6; or BMI ≥ 30 kg/m 1, 2
§Suspected virologic failure time point. 1
- Virologically suppressed adults (HIV-1 RNA <50 copies/mL)
- No present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class
- No contraindications or potential drug-drug interactions
See SmPC for full list of contraindications and drug-drug interactions.
- May express interest in less-frequent dosing, or benefit from it
- Due to challenges with daily HIV therapy, such as:
- Fear of disclosure
- Anxiety with staying adherent
- Daily reminder of HIV
- Fatigue with taking daily ARVs
- Able to commit to every 2-month visits and understands the importance of adhering to the schedule
▼These medicinal products are subject to additional monitoring.
VOCABRIA (cabotegravir) injection is indicated, in combination with REKAMBYS (rilpivirine) injection, for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. 1, 2
VOCABRIA and REKAMBYS injections are contraindicated in case of hypersensitivity to the active substance or to any of the excipients and must not be co-administered with rifampicin, rifapentine, rifabutin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, dexamethasone (except as a single dose treatment), St John’s wort or proton pump inhibitors (oral rilpivirine). 1, 2
OAT1/3 can be inhibited by cabotegravir, therefore caution is required when co-dosing with methotrexate. VOCABRIA and REKAMBYS injections are not recommended in HBV patients, and monitoring of liver function is recommended in HCV patients. During pregnancy VOCABRIA and REKAMBYS injections are not recommended unless the expected benefit justifies the potential risk to the foetus. 1, 2
The most frequently reported adverse reactions from ATLAS-2M every 2-month dosing were injection site reactions (76%), headache (7%) and pyrexia (7%). To minimise the risk of developing viral resistance it is essential to adopt an alternative, fully suppressive antiretroviral regimen no later than two months after the final injections of VOCABRIA and REKAMBYS when dosed every 2-month. 1, 2
For all safety information, please refer to the full Summary of Product Characteristics.
REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
©2021 ViiV Healthcare group of companies or its licensor.